Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
Calleja Hernández, Miguel Ángel (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Albanell Mestres, Joan (Hospital del Mar (Barcelona, Catalunya))
Aranda, Enrique (Hospital Universitario Reina Sofia-CIBERONC)
Garcia-Foncillas, Jesús (Hospital Universitario Fundación Jiménez Díaz)
Feliu, Anna (Institut d'Investigació Biomèdica Sant Pau)
Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Oyagüez, Itziar (Pharmacoeconomics and Outcomes Research Iberia)
Salinas-Ortega, Laura (Pharmacoeconomics and Outcomes Research Iberia)
Alvarez, Javier Soto (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	To assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. A 3-year budget impact analysis model was adapted to estimate the cost of introducing biosimilars of bevacizumab in the SNHS for the adult population who were candidates to receive treatment with bevacizumab. Values for the estimation of the population were obtained from the literature and were validated by an expert panel. In this analysis only pharmaceutical costs (, year 2021) obtained from official databases were considered. A sensitivity analysis was performed to examine the robustness of the model. The introduction of bevacizumab biosimilars would generate an annual cost saving of 11 558 268 (-5. 1%) for the first year with a penetration share of biosimilars from 30. 0%, 29 126 373 (-8. 5%) for the second year with a share of 50. 0% and 52 361 778 (-13. 6%) for the third year with a share of 80. 0%. The total pharmaceutical costs of the scenario without biosimilars are 227 033 352 for the first year, 342 663 209 for the second year and 385 013 076 for the third year. In contrast, the pharmaceutical costs of the scenario with bevacizumab biosimilars are 215 475 084, 313 536 836 and 332 651 297 for years 1, 2 and 3, respectively. The introduction of biosimilars in the Spanish Health System would generate saving costs in the pharmacological budget to boost biological drugs from the first year. European Association of Hospital Pharmacists 2023.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Antineoplastic agents ; Health care economics and organizations ; Medical oncology ; Pharmaceutical ; Public health
Published in:	European Journal of Hospital Pharmacy, Vol. 30 Núm. E1 (2023) , p. E40-E47, ISSN 2047-9964

DOI: 10.1136/ejhpharm-2021-002955
PMID: 34810173

8 p, 1.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles